942919-24-6

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
• Synonyms: 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-;1-Phenylsulfonyl-7-azaind...;1-Phenylsulfonyl-7-azaindole-4-boronic acid pinacol ester;1-(benzenesulfonyl)-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine;1-(Benzenesulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine;1-(Phenylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pryrolo[2,3-b]pyridine;(1-(PHENYLSULFONYL)-1H-PYRROLO[2,3-B]PYRIDIN-4-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 942919-24-6
• Molecular Formula: C₁₉H₂₁BN₂O₄S
• Molecular Weight: 384.27
• Mol File: 942919-24-6.mol

Chemical Properties

• Boiling Point: 565.1°C at 760 mmHg
• Flash Point: 295.6°C
• Appearance: /
• Density: 1.25g/cm³
• Vapor Pressure: 8.58E-13mmHg at 25°C
• Refractive Index: 1.601
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-(942919-24-6)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-(942919-24-6)

Safety Data

• Hazardous Substances Data: 942919-24-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)is used as a building block for the synthesis of complex organic molecules, leveraging its structural features to create a diverse range of compounds with potential applications across various fields.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)is utilized as a potential precursor for the synthesis of biologically active molecules. Its unique structure allows for the development of new drugs with specific therapeutic targets.
Used in Material Science:
1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)is also used in the development of new materials with tailored electronic or optical properties. 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-'s ability to form specific bonds and its structural characteristics make it a candidate for creating materials with applications in various high-tech industries.

InChI:InChI=1/C19H21BN2O4S/c1-18(2)19(3,4)26-20(25-18)16-10-12-21-17-15(16)11-13-22(17)27(23,24)14-8-6-5-7-9-14/h5-13H,1-4H3

Upstream product

• 889939-25-7 1-(benzenesulfonyl)-4-bromo-1H-pyrrolo[2,3-b]pyridine 
• 73183-34-3 bis(pinacol)diborane 
• 271-63-6 7-Azaindole 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 348640-06-2 4-bromo-7-azaindole 
• 98-09-9 benzenesulfonyl chloride 

Downstream Products

• 943321-97-9 4-(4-bromo-2-thienyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 943322-36-9 4-bromo-5-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-2-thiophenecarboxylic acid 
• 1261080-57-2 (S)-N-(1-amino-3-(2,4-dichlorophenyl)propan-2-yl)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiazole-5-carboxamide 
• 1261080-71-0 2-(1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)thiazole-5-carboxylic acid 
• 1261080-72-1 (S)-N-(1-azido-3-(2,4-dichlorophenyl)propan-2-yl)-2-(1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)thiazole-5-carboxamide 
• 1261080-73-2 (S)-N-(1-azido-3-(2,4-dichlorophenyl)propan-2-yl)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiazole-5-carboxamide 
• 1261080-70-9 ethyl 2-(1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)thiazole-5-carboxylate 
• 1228217-24-0 2-{4-[2-(4-fluorophenyl)-8-methyl-3-{1-[phenylsulphonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl}imidazo[1,2-b]pyridazin-6-yl]piperazin-1-yl}ethanol 
• 1228217-10-4 (Cis)-2-(4-Fluorophenyl)-8-methyl-6-[(cis)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine 
• 1228217-19-3 6-Chloro-2-(4-fluorophenyl)-8-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1, 2-b]pyridazine 
• 1228632-59-4 (S)-1-{4-[2-(4-fluorophenyl)-8-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl]piperazin-1-yl}propan-2-ol 
• 1228632-56-1 (R)-1-{4-[2-(4-fluorophenyl)-8-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl]piperazin-1-yl}propan-2-ol 
• 1228216-99-6 2-{4-[2-(4-fluorophenyl)-8-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl]piperazin-1-yl}ethanol 
• 1346685-04-8 dimethyl 3-bromo-4-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-2,5-thiophenedicarboxylate 

Relevant articles and documents

Discovery of 1,8-disubstituted-[1,2,3]triazolo[4,5-c]quinoline derivatives as a new class of Hippo signaling pathway inhibitors

Inhibitors of the Hippo signaling pathway have been demonstrated to have a potential clinical application in cases such as tissue repair and organ regeneration. However, there is a lack of potent Hippo pathway inhibitors at present. Herein we report the discovery of a series of 1,8-disubstituted-[1,2,3]triazolo[4,5-c]quinoline derivatives as a new class of Hippo pathway inhibitors by utilizing a cell line-based screening model (A549-CTGF). Structure-activity relationship (SAR) of these compounds was also discussed. The most potent compound in the A549-CTGF cell assay, 11g, was then evaluated by real-time PCR and immunofluorescence assays. Overall, this study provides a starting point for later drug discovery targeting the Hippo signaling pathway.

1H-[1,2,3]triazolo[4,5-c]quinoline derivative, preparation method and uses thereof

The invention belongs to the field of chemical medicine, particularly relates to a 1H-[1,2,3]triazolo[4,5-c]quinoline derivative, a preparation method and uses thereof, and provides a 1H-[1,2,3]triazolo[4,5-c]quinoline derivative, which has a structure represented by a formula I. The invention further provides a preparation method and uses of the 1H-[1,2,3]triazolo[4,5-c]quinoline derivative. Theformula I is defined in the specification.

5 - thiazole amides and biological applications

The invention relates to a 5-thiazole amide compound and biology application thereof. The 5-thiazole amide compound has a general formula (I) described in the specification and is used for targeting an AKT/PKB kinase (ATP binding site). Experiments prove that a thiazole amide AKT inhibitor can remarkably inhibit the activity of the AKT kinase in vitro and has strong proliferation inhibition function on various tumor cells with high AKT activity, which indicate that the 5-thiazole amide compound can be used for preparing drugs for resisting tumors.

New thiazole carboxamides as potent inhibitors of Akt kinases

A new series of 2-substituted thiazole carboxamides were identified as potent pan inhibitors against all three isoforms of Akt (Akt1, Akt2 and Akt3) by systematic optimization of weak screening hit N-(1-amino-3-phenylpropan-2-yl)- 2-phenylthiazole-5-carboxamide (1). One of the most potent compounds, 5m, inhibited the kinase activities of Akt1, Akt2 and Akt3 with IC50 values of 25, 196 and 24 nM, respectively. The compound also potently inhibited the phosphorylation of downstream MDM2 and GSK3β proteins, and displayed strongly antiproliferative activity in prostate cancer cells. The inhibitors might serve as lead compounds for further development of novel effective anticancer agents.

Discovery of GSK1070916, a potent and selective inhibitor of aurora B/C kinase

The Aurora kinases play critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. Selective inhibitors may provide a new therapy for the treatment of tumors with Aurora kinase amplification. Herein we describe our lead optimization efforts within a 7-azaindole-based series culminating in the identification of GSK1070916 (17k). Key to the advancement of the series was the introduction of a 2-aryl group containing a basic amine onto the azaindole leading to significantly improved cellular activity. Compound 17k is a potent and selective ATP-competitive inhibitor of Aurora B and C with Ki* values of 0.38 ± 0.29 and 1.5 ± 0.4 nM, respectively, and is >250-fold selective over Aurora A. Biochemical characterization revealed that compound 17k has an extremely slow dissociation half-life from Aurora B (>480 min), distinguishing it from clinical compounds 1 and 2. In vitro treatment of A549 human lung cancer cells with compound 17k results in a potent antiproliferative effect (EC50 = 7 nM). Intraperitoneal administration of 17k in mice bearing human tumor xenografts leads to inhibition of histone H3 phosphorylation at serine 10 in human colon cancer (Colo205) and tumor regression in human leukemia (HL-60). Compound 17k is being progressed to human clinical trials.

Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors

A pyrrolopyridinyl thiophene carboxamide 7 was discovered as a tractable starting point for a lead optimization effort in an AKT kinase inhibition program. SAR studies aided by a co-crystal structure of 7 in AKT2 led to the identification of AKT inhibitor

AZAINDOLE INHIBITORS OF AURORA KINASES

The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including s

INHIBITORS OF Akt ACTIVITY

Invented are novel thiophene compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.